Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.

Trial Details

NCT ID
NCT07489534
Phase
PHASE2
Sponsor
Daihong Liu
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • PD-1Ab21-BCMA CAR-T cell immunotherapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age: Over 14 years old
  • Diagnosed with multiple myeloma accompanied by renal dysfunction, received ≥ 2 courses of clinical first-line treatment, evaluated efficacy above P…
  • The hospital examination meets the following indicators:
  • ECOG physical status score 0-2 or KPS score\>80 points

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →